ASXL1 Frameshift Mutations Drive Inferior Outcomes in CMML without Negative Impact in MDS

In myelodysplastic syndromes (MDS), mutation of ASXL1 was least predictive of inferior outcomes and type of mutation was not analyzed. In contrast, mutational analysis in chronic myelomonocytic leukemia (CMML) has identified ASXL1 mutation as the only mutation to be independently predictive of inferior survival when including only nonsense and frameshift mutations.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: David Sallman, Jinming Song, Thomas Cluzeau, Christine Vaupel, Najla Al Ali, Jeffrey Lancet, Jeff Hall, Alan List, Eric Padron, Rami Komrokji Source Type: research